Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio (TRML)
NASDAQ:TRML
Tourmaline Bio (TRML) Stock Price & Analysis
285 Followers
TRML Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.18 - $48.31
Previous Close$14.91
Volume203.24K
Average Volume (3M)393.79K
Market Cap
$382.39M
Enterprise Value$89.71M
Total Cash (Recent Filing)$293.06M
Total Debt (Recent Filing)$376.00K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 13, 2024EPS Estimate
-$0.67Last Dividend Ex-Date
Oct 20, 2023Dividend Yield101.39%
Share Statistics
EPS (TTM)-6.50
Shares Outstanding25,646,509
10 Day Avg. Volume313,322
30 Day Avg. Volume393,785
Standard Deviation0.27
R-Squared0.16
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.91
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)8.90
P/FCF Ratio9.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.89
Forecast
1Y Price Target
$48.50Price Target Upside218.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Tourmaline Bio News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe upcoming Phase 3 pivotal trial for TOUR006 as a first-line treatment for thyroid eye disease signifies progress in the company's clinical development pipeline.
Financial PerformanceNet loss was $13.3M, or ($0.55) per share, lower than the estimated loss of $16.0M.
Regulatory MilestonesReceiving IND clearance for the Phase 2 trial of TOUR006 in cardiovascular disease suggests regulatory confidence in the company's research and potential for expanding treatment applications.
Bears Say
Clinical Trial ResultsRecent disappointing data from Chugai’s Phase 3 LUMINESCE trial of satralizumab (anti-IL-6) in myasthenia gravis (MG) has pressured TRML shares.
Financial PerformanceNet loss totaled $42.1M in 2023.
Share Price PerformanceThe recent drop in TRML share price as a result of the data from the Phase 3 LUMINESCE trial of Enspryng (satralizumab, an anti-IL-6 antibody) in generalized myasthenia gravis (gMG) is unwarranted.
---
Ownership Overview
Currently, No data available
---
TRML FAQ
What was Tourmaline Bio’s price range in the past 12 months?
Tourmaline Bio lowest stock price was $9.18 and its highest was $48.31 in the past 12 months.
What is Tourmaline Bio’s market cap?
Currently, no data Available
When is Tourmaline Bio’s upcoming earnings report date?
Tourmaline Bio’s upcoming earnings report date is May 13, 2024 which is 69 days ago.
How were Tourmaline Bio’s earnings last quarter?
Tourmaline Bio released its earnings results on Mar 19, 2024. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.708 by -$0.102.
Is Tourmaline Bio overvalued?
According to Wall Street analysts Tourmaline Bio’s price is currently Undervalued.
Does Tourmaline Bio pay dividends?
Tourmaline Bio pays a Notavailable dividend of $1.51 which represents an annual dividend yield of 101.39%. See more information on Tourmaline Bio dividends here
What is Tourmaline Bio’s EPS estimate?
Tourmaline Bio’s EPS estimate is -$0.67.
How many shares outstanding does Tourmaline Bio have?
Tourmaline Bio has 25,646,510 shares outstanding.
What happened to Tourmaline Bio’s price movement after its last earnings report?
Tourmaline Bio reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.708. Following the earnings report the stock price went down -0.414%.
Which hedge fund is a major shareholder of Tourmaline Bio?
Among the largest hedge funds holding Tourmaline Bio’s share is Woodline Partners LP. It holds Tourmaline Bio’s shares valued at 4M.
---
Tourmaline Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.50 (218.87% Upside)
$48.50 (218.87% Upside)
Hedge Fund Trend
Increased
By 157.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.41%
12-Months-Change
Fundamentals
Return on Equity
-18.60%
Trailing 12-Months
Asset Growth
108.08%
Trailing 12-Months
Company Description
Tourmaline Bio
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
---
TRML Stock 12 Month Forecast
Average Price Target
$48.50
▲(218.87% Upside)
Technical Analysis
Best Analysts Covering TRML
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-22.47%
reiterated a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -22.47% per trade.
---